Liang R, Chan T K, Todd D
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Cancer Chemother Pharmacol. 1988;21(1):68-70. doi: 10.1007/BF00262743.
Twenty-nine evaluable patients with acute nonlymphoblastic leukemia (ANLL), either in relapse or resistant to initial induction therapy (ara C, daunorubicin + etoposide), received the ATA regime consisting of 100 mg/m2 per day Ara C by i.v. infusion for 4-5 days, 100 mg/m2 per day thioguanine orally for 4-5 days, and 100 mg/m2 per day amsacrine i.v. for 2-5 days. Each patient received 1-6 courses (median, 2) of the regime. There were 7 (24%) complete responders, and their duration of responses were 2, 2, 2, 5, 9+, 19, and 24+ months. The complete remission (CR) rate of patients who had a previous CR beyond 6 months (6/13, 46%) was significantly better (X2 = 4.25, p less than 0.05) than that of those who had previously relapsed within 6 months or were refractory to primary induction chemotherapy (1/16, 6%). The two groups of patients had similar patterns of treatment failure. Myelosuppression was the major toxic side effect, and nonhematological toxicities were mild and acceptable.
29例可评估的急性非淋巴细胞白血病（ANLL）患者，处于复发状态或对初始诱导治疗（阿糖胞苷、柔红霉素+依托泊苷）耐药，接受了ATA方案治疗，该方案包括：阿糖胞苷100mg/m²，静脉输注，每日1次，共4 - 5天；硫鸟嘌呤100mg/m²，口服，每日1次，共4 - 5天；安吖啶100mg/m²，静脉输注，每日1次，共2 - 5天。每位患者接受1 - 6个疗程（中位数为2个疗程）的该方案治疗。有7例（24%）完全缓解者，其缓解持续时间分别为2、2、2、5、9 +、19和24 +个月。先前完全缓解超过6个月的患者（6/13，46%）的完全缓解（CR）率显著高于那些先前在6个月内复发或对初始诱导化疗耐药的患者（1/16，6%）（X² = 4.25，p < 0.05）。两组患者的治疗失败模式相似。骨髓抑制是主要的毒副作用，非血液学毒性轻微且可接受。
